Meloxiway 5 mg/mL injection

DOGS

Alleviation of inflammation and pain in both acute and chronic musculoskeletal disorders
Reduction of post-operative pain and inflammation following orthopaedic and soft tissue surgery

CATS

Reduction of pain after surgery

Management of febrile conditions in combination with approriate antibiotics

DOGS

MUSCULOSKELETAL DISORDERS: Single subcutaneous injection at a dosage of 0.2 mg meloxicam/kg bodyweight (i.e., 0.4 mL/10 kg bodyweight). Meloxiway 5mg/mL Injection should be used for continuation of treatment at a dosage of 0.1 mg meloxicam/kg bodyweight, 24 hours after administration of the injection.

REDUCTION OF POST-OPERATIVE PAIN: Single intravenous or subcutaneous injection at a dosage of 0.2 mg meloxicam/kg bodyweight (i.e., 0.4 mL/10 kg bodyweight) before surgery, for example at the time of induction of anaesthesia.

CATS

REDUCTION OF POST-OPERATIVE PAIN: Single subcutaneous injection at a dosage of 0.3 mg meloxicam/kg bodyweight (i.e., 0.06 mL/kg bodyweight) directly prior to induction of anaesthesia.

MANAGEMENT OF FEBRILE CONDITIONS: Single subcutaneous injection at a dosage of 0.3 mg meloxicam/kg bodyweight (i.e., 0.06 mL/kg bodyweight).

20 mL vial

Meloxiway is a non-steroidal anti-inflammatory drug (NSAID) of the oxicam class which acts by inhibition of prostaglandin synthesis, thereby exerting anti-inflammatory, anti-exudative, analgesic and antipyretic effects. It reduces leukocyte infiltration into the inflamed tissue.

Hypovolaemia or hypotension should be corrected prior to use of the product.

Disclaimer

–